MTOR and melanoma: They found these inhibitors to simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cell lines, yielding dynamic changes in mTOR(RPTOR) signaling.